Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.
Feuerstein graduated from Emory University with a bachelor's degree in political science.
Recent Articles By The Author
The Good (Celgene) and Bad (Biogen) Ways to Deliver Drug Revenue Growth
This week's earnings announcements from Celgene and Biogen provided a contrast between volume- and price-driven revenue growth.
ProQR Cystic Fibrosis Drug Passes First, Early Efficacy Test
The development of QR-010 is still early but Thursday's preliminary study results were encouraging enough to boost ProQR's stock price.
Pardon Me, but I Have a Few Things to Say... Vertex, Biogen, Ariad, Sarepta
More about Vertex' Debbie Downer gene, Biogen's Alzheimer's spin and Sarepta caught in drug launch purgatory.
AstraZeneca Is Now a Competitive Threat to Tesaro in Ovarian Cancer Maintenance Therapy
AstraZeneca's Lynparza significantly delayed the recurrence of tumors in patients with ovarian cancer compared to a placebo, according to results from a phase III study announced by the company Wednesday.
Vertex Pharma Moves Next-Generation Cystic Fibrosis Drugs Into New Clinical Trials
Vertex hopes the new drugs will improve on the efficacy and tolerability of Orkambi, the first combination therapy approved for cystic fibrosis in 2015.